{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:32:36Z","timestamp":1790112756136,"version":"4.0.1"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-025-02247-z","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T23:28:40Z","timestamp":1741908520000},"page":"1123-1125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lesson for the clinical nephrologist:\u00a0glucagon-like peptide-1 receptor agonists (GLP-1 RA) in a patient with obesity and diabetic kidney disease on peritoneal dialysis"],"prefix":"10.1093","volume":"38","author":[{"given":"Pavlo","family":"Yavorskiy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4414-4597","authenticated-orcid":false,"given":"Silvio","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ida","family":"Maiorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Petrizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"De Nicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Garofalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"issue":"2","key":"2247_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P et al (2024) Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 391(2):109\u2013121. https:\/\/doi.org\/10.1056\/NEJMoa2403347","journal-title":"N Engl J Med"},{"issue":"9","key":"2247_CR2","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1093\/ckj\/sfac090","volume":"15","author":"M Touzot","year":"2022","unstructured":"Touzot M, Ure\u00f1a-Torres P, Dupuy O (2022) Semaglutide for treatment of obesity in hemodialysis patients waiting for a kidney transplant: new hope? Clin Kidney J 15(9):1782\u20131784. https:\/\/doi.org\/10.1093\/ckj\/sfac090","journal-title":"Clin Kidney J"},{"issue":"12","key":"2247_CR3","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.1111\/dom.15967","volume":"26","author":"L Vanek","year":"2024","unstructured":"Vanek L, Kurnikowski A, Krenn S, Mussnig S, Hecking M (2024) Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: a prospective, observational, open-label study. Diabetes Obes Metab 26(12):5931\u20135941. https:\/\/doi.org\/10.1111\/dom.15967","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2247_CR4","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/nep.14277","volume":"29","author":"R Wallace","year":"2024","unstructured":"Wallace R, Hamblin PS, Tully E, Tran J, Nelson C, Levidiotis V (2024) Case report of the successful use of semaglutide to achieve target BMI prior to renal transplant in two patients with end-stage-kidney-disease. Nephrology (Carlton) 29(6):371\u2013374. https:\/\/doi.org\/10.1111\/nep.14277","journal-title":"Nephrology (Carlton)"},{"issue":"1","key":"2247_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.krcp.2015.12.007","volume":"35","author":"WK Lo","year":"2016","unstructured":"Lo WK (2016) Metabolic syndrome and obesity in peritoneal dialysis. Kidney Res Clin Pract 35(1):10\u201314. https:\/\/doi.org\/10.1016\/j.krcp.2015.12.007","journal-title":"Kidney Res Clin Pract"},{"issue":"1","key":"2247_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40620-019-00673-4","volume":"33","author":"S Borrelli","year":"2020","unstructured":"Borrelli S, De Nicola L, Minutolo R et al (2020) Sodium toxicity in peritoneal dialysis: mechanisms and \u201csolutions.\u201d J Nephrol 33(1):59\u201368. https:\/\/doi.org\/10.1007\/s40620-019-00673-4","journal-title":"J Nephrol"},{"issue":"2","key":"2247_CR7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.2215\/CJN.10300819","volume":"15","author":"C Kennedy","year":"2020","unstructured":"Kennedy C, Bargman J (2020) Peritoneal dialysis in the obese patient. Clin J Am Soc Nephrol 15(2):276\u2013278. https:\/\/doi.org\/10.2215\/CJN.10300819","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2247_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/ncpneph1022","volume":"5","author":"YE Bogaert","year":"2009","unstructured":"Bogaert YE, Linas S (2009) The role of obesity in the pathogenesis of hypertension. Nat Clin Pract Nephrol 5(2):101\u2013111. https:\/\/doi.org\/10.1038\/ncpneph1022","journal-title":"Nat Clin Pract Nephrol"},{"issue":"Supplement_1","key":"2247_CR9","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee (2025) 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025. Diabetes Care 48(Supplement_1):S181\u2013S206. https:\/\/doi.org\/10.2337\/dc25-S009","journal-title":"Diabetes Care"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02247-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-025-02247-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02247-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:59:06Z","timestamp":1777564746000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/38\/3\/1123\/8457162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":9,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["2247"],"URL":"https:\/\/doi.org\/10.1007\/s40620-025-02247-z","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"27 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LDN has received fees for lectures and scientific consultation from ASTELLAS, BAYER, ASTRAZENECA. SB has received fees for lectures from ASTRAZENECA, VIFOR, BAXTER. KE has been a member on advisory boards for Eli Lilly & Co., NovoNordisk, Lifescan, Roche, Bayer and has received honoraria for these activities. Other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institutional review board approval was given for this case report. The study was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All procedures in this study involving human participants followed the 1964 Helsinki Declaration and its later amendments and the ethical standards of the institutional and national research committees.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consent was obtained and the participant has consented to the submission of the case report to the journal.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}